Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.20099 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Shawn G Kwatra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Prurigo, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Background
Prurigo nodularis (PN) is an intensely pruritic disease characterized by itchy nodules on the trunk/extremities; it is often accompanied by skin pain and sleep disruption with negative impacts on the quality of life (QoL). The patient‐reported outcome (PRO) instruments, Worst Itch‐Numeric Rating Scale (WI‐NRS), Skin Pain‐NRS, Sleep‐NRS and Dermatology Life Quality Index (DLQI) have been psychometrically validated and the clinically meaningful within‐patient improvement thresholds (responder definition) have been established through data pooled from the two Phase‐3 trials (PRIME, NCT04183335 and PRIME2, NCT04202679) of dupilumab in adults with PN uncontrolled on topical therapies.
Objectives
To estimate the proportion of dupilumab‐treated patients (vs. placebo) achieving clinically meaningful improvement in itch, skin pain, sleep and QoL, either alone or in combination, from the data pooled from PRIME and PRIME2 trials.
Methods
The patient‐level data pooled from the two Phase‐3 trials ( N = 311) were used for this post hoc analysis. Thresholds of clinically meaningful within‐patient improvement in PRO instrument scores from baseline at Week 24 used for defining responders were 4 (WI‐NRS and Skin Pain‐NRS), 2 (Sleep‐NRS) and 9 points (DLQI). The proportion of dupilumab‐treated patients, versus placebo, achieving the thresholds, and the time taken to achieve the thresholds were evaluated for the individual and combination of PROs.
Results
Responder rates were significantly higher with dupilumab, versus placebo at Week 24 for WI‐NRS (58.8% vs. 19.0%, p < 0.0001), Skin Pain‐NRS (49.7% vs. 20.9%, p < 0.0001), Sleep‐NRS (42.5% vs. 23.4%, p < 0.0001) and DLQI (64.7% vs. 22.8%, p < 0.0001). Proportion of patients achieving simultaneous improvement in symptoms and QoL (24.8% vs. 6.3%, p < 0.0001) were significantly higher in dupilumab‐treated patients versus placebo. The time needed for achieving clinically meaningful improvement in symptoms were significantly lower in dupilumab‐treated patients, versus placebo.
Conclusions
Significantly greater proportion of dupilumab‐treated patients with PN, versus placebo, demonstrated clinically meaningful improvements in PRO measures of symptoms and QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
- University of Miami, Miami, Florida, USA.
- Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.
- IQVIA, Paris, France.
- Sanofi, Gentilly, France.
- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
ORCID-Profile: Shawn G Kwatra, Sonja Ständer, Ashish Bansal, Donia Bahloul
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Kwatra, S. G., Yosipovitch, G., Ständer, S., Guillemin, I., Msihid, J., Bansal, A., Makhija, M., Wiggins, S., Zahn, J., Thomas, R. B., & Bahloul, D. (2024). Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20099
Vancouver
Kwatra SG, Yosipovitch G, Ständer S, Guillemin I, Msihid J, Bansal A, et al. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.20099
BibTeX
@article{Kwatra2024,
author = {Kwatra, Shawn G and Yosipovitch, Gil and Ständer, Sonja and Guillemin, Isabelle and Msihid, Jérôme and Bansal, Ashish and Makhija, Melanie and Wiggins, Simmi and Zahn, Joseph and Thomas, Ryan B and Bahloul, Donia},
title = {Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.20099}
}
EUVIMED